TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
Transcenta, Biologics, Antibody, Claudin 18.2
Our research department has extensive experience in drug discovery and development. Members of the team generally have disease biology, antibody immunization and screening, protein sciences and antibody engineering, in vitro and in vivo pharmacology, and biomarker research background. Our unique IMTB technology platform enables us to generate candidate molecules with enhanced druggability attributes and strong intellectual property position. Leveraging this platform, we have independently discovered Osemitamab (TST001), TST005, TST003, TST004, TST010, TST012, TST013, TST008, TST801 etc.,
The IMTB technology platform, enables us to generate antibodies to both non-conserved and conserved proteins, which are difficult to generate in rodents, and to discover hidden epitopes that are challenging to discover using conventional platforms. This allows us to obtain lead candidate antibodies with expanded epitope diversity, differentiated and robust CMC profiles, resulting in selecting candidate molecules with enhanced druggability attributes and intellectual property position.